Adverse outcomes between VMAT2 and anticholinergics in tardive dyskinesia: A target trial emulation

Key Points

• To compare the safety and efficacy of VMAT2 inhibitors with anticholinergic agents for managing tardive dyskinesia.
• Conducted a real-world study evaluating therapeutic outcomes.
• Compared adverse outcomes between VMAT2 inhibitors and anticholinergics.
• Assessed potential clinical benefits of VMAT2 inhibitors.
• VMAT2 inhibitors may have a lower incidence of adverse outcomes compared to anticholinergics.
• The findings indicate a potential clinical advantage for using VMAT2 inhibitors in tardive dyskinesia management.
• Further long-term validation of these results is warranted.

Abstract